A Phase 2, Single-Arm, Open-label Study of Brentuximab Vedotin in Chinese Patients With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
收藏DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007567/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of
brentuximab vedotin as a single agent in Chinese participants with relapsed/refractory CD30+
Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL).
提供机构：
Vivli
创建时间：
2021-12-22
